靶向单胺受体和谷氨酸系统抗抑郁药的研究进展.pdfVIP

Pharmacy Information 药物资讯, 2016, 5(2), 38-44 Published Online May 2016 in Hans. /journal/pi /10.12677/pi.2016.52007 Research Progress of the Antidepressants Targeting the Monomine Receptors and Glutamate System Yingying Ren1,2, Liangliang Zhou1,2, Huali Wu1,2, Jing Shang1,2* 1 Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing Jiangsu 2 State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing Jiangsu th rd th Received: May 4 , 2016; accepted: May 23 , 2016; published: May 26 , 2016 Copyright © 2016 by authors and Hans Publishers Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). /licenses/by/4.0/ Abstract Depression is a kind of psychiatric disorders and is characterized by persistent low mood, cogni- tive impairment and behavioral change. Monoamine neurotransmitter reuptake inhibitors are the most common used antidepressants in clinic, but it needs weeks to work and depressed patients may show resistance to the treatment. With the research on the pathogenesis of depression pro- gressing, species of antidepressants have emerged. Agents regulating monoamine (serotonin, do- pamine, noradrenaline, etc.) receptors and glutamate receptors including NMDA receptor, AMPA receptor and metabotropic glutamate receptor and agents that inhibit glutamate release gradually become antidepressant research hotspots with the advantage of rapid-onset. Here, antidepres- sants targeting monoamine receptors and glutamate system in the market and on clinical trial are reviewed, thus providing guidance for the developing trends of new type antidepressants. Keywords